
Steven A Julious

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7141846/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Expected Value of Sample Information to Guide the Design of Group Sequential Clinical Trials. Medical Decision Making, 2022, 42, 461-473.	2.4	4
2	Adjusting for bias in the mean for primary and secondary outcomes when trials are in sequence. Pharmaceutical Statistics, 2022, 21, 460-475.	1.3	4
3	Practical guide to sample size calculations: Installation of the app <scp>SampSize</scp> . Pharmaceutical Statistics, 2022, , .	1.3	0
4	Self-managed, computerised word finding therapy as an add-on to usual care for chronic aphasia post-stroke: An economic evaluation. Clinical Rehabilitation, 2021, 35, 703-717.	2.2	9
5	Risk Predictors and Symptom Features of Long COVID Within a Broad Primary Care Patient Population Including Both Tested and Untested Patients. Journal of Pragmatic and Observational Research, 2021, Volume 12, 93-104.	1.5	32
6	Sample sizes for cluster-randomised trials with continuous outcomes: Accounting for uncertainty in a single intra-cluster correlation estimate. Statistical Methods in Medical Research, 2021, 30, 2459-2470.	1.5	6
7	Characteristics of patients in platform C19, a COVID-19 research database combining primary care electronic health record and patient reported information. PLoS ONE, 2021, 16, e0258689.	2.5	2
8	The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. Trials, 2020, 21, 528.	1.6	10
9	The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. BMJ, The, 2020, 369, m115.	6.0	57
10	How can health economics be used in the design and analysis of adaptive clinical trials? A qualitative analysis. Trials, 2020, 21, 252.	1.6	4
11	Computerised speech and language therapy or attention control added to usual care for people with long-term post-stroke aphasia: the Big CACTUS three-arm RCT. Health Technology Assessment, 2020, 24, 1-176.	2.8	24
12	Self-managed, computerised speech and language therapy for patients with chronic aphasia post-stroke compared with usual care or attention control (Big CACTUS): a multicentre, single-blinded, randomised controlled trial. Lancet Neurology, The, 2019, 18, 821-833.	10.2	116
13	Progression criteria in trials with an internal pilot: an audit of publicly funded randomised controlled trials. Trials, 2019, 20, 493.	1.6	28
14	A Review of Clinical Trials With an Adaptive Design and Health Economic Analysis. Value in Health, 2019, 22, 391-398.	0.3	18
15	Calculation of confidence intervals for a finite population size. Pharmaceutical Statistics, 2019, 18, 115-122.	1.3	4
16	Practical help for specifying the target difference in sample size calculations for RCTs: the DELTA2 five-stage study, including a workshop. Health Technology Assessment, 2019, 23, 1-88.	2.8	15
17	Are pilot trials useful for predicting randomisation and attrition rates in definitive studies: A review of publicly funded trials. Clinical Trials, 2018, 15, 189-196.	1.6	34
18	Development process of a consensus-driven CONSORT extension for randomised trials using an adaptive design. BMC Medicine, 2018, 16, 210.	5.5	28

#	Article	IF	CITATIONS
19	DELTA ² guidance on choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial. BMJ: British Medical Journal, 2018, 363, k3750.	2.3	90
20	DELTA2 guidance on choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial. Trials, 2018, 19, 606.	1.6	50
21	Choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial $\hat{a} \in$ "the development of the DELTA2 guidance. Trials, 2018, 19, 542.	1.6	7
22	Multicentre, double-blind, crossover trial to identify the Optimal Pathway for TreatIng neurOpathic paiN in Diabetes Mellitus (OPTION-DM): study protocol for a randomised controlled trial. Trials, 2018, 19, 578.	1.6	12
23	At-risk children with asthma (ARC): a systematic review. Thorax, 2018, 73, 813-824.	5.6	87
24	Guidance for using pilot studies to inform the design of intervention trials with continuous outcomes. Clinical Epidemiology, 2018, Volume 10, 153-157.	3.0	137
25	Open-label, cluster randomised controlled trial and economic evaluation of a brief letter from a GP on unscheduled medical contacts associated with the start of the school year: the PLEASANT trial. BMJ Open, 2018, 8, e017367.	1.9	2
26	Protocol for a systematic review to identify and weight the indicators of risk of asthma exacerbations in children aged 5–12 years. Npj Primary Care Respiratory Medicine, 2017, 27, 16088.	2.6	1
27	Economic Evaluations Alongside Efficient Study Designs Using Large Observational Datasets: the PLEASANT Trial Case Study. Pharmacoeconomics, 2017, 35, 561-573.	3.3	13
28	Corrections: The disagreeable behaviour of the kappa statistic. Pharmaceutical Statistics, 2017, 16, 95-95.	1.3	0
29	Can emergency medicine research benefit from adaptive design clinical trials?. Emergency Medicine Journal, 2017, 34, 243-248.	1.0	4
30	Choosing the target difference (â€~effect size') for a randomised controlled trial - DELTA2 guidance protocol. Trials, 2017, 18, 271.	1.6	10
31	Recruitment and retention of participants in randomised controlled trials: a review of trials funded and published by the United Kingdom Health Technology Assessment Programme. BMJ Open, 2017, 7, e015276.	1.9	335
32	Design considerations and analysis planning of a phase 2a proof of concept study in rheumatoid arthritis in the presence of possible non-monotonicity. BMC Medical Research Methodology, 2017, 17, 149.	3.1	6
33	PPI in the PLEASANT trial: involving children with asthma and their parents in designing an intervention for a randomised controlled trial based within primary care. Primary Health Care Research and Development, 2016, 17, 536-548.	1.2	12
34	Automated telephone communication systems for preventive healthcare and management of long-term conditions. The Cochrane Library, 2016, 2016, CD009921.	2.8	83
35	Practical guide to sample size calculations: an introduction. Pharmaceutical Statistics, 2016, 15, 68-74.	1.3	34
36	Practical guide to sample size calculations: nonâ€inferiority and equivalence trials. Pharmaceutical Statistics, 2016, 15, 80-89.	1.3	74

#	Article	IF	CITATIONS
37	Practical guide to sample size calculations: superiority trials. Pharmaceutical Statistics, 2016, 15, 75-79.	1.3	14
38	Adaptive designs undertaken in clinical research: a review of registered clinical trials. Trials, 2016, 17, 150.	1.6	66
39	Pilot Studies in clinical research. Statistical Methods in Medical Research, 2016, 25, 995-996.	1.5	14
40	Estimating the sample size for a pilot randomised trial to minimise the overall trial sample size for the external pilot and main trial for a continuous outcome variable. Statistical Methods in Medical Research, 2016, 25, 1057-1073.	1.5	903
41	Understanding Variation in Sets of N-of-1 Trials. PLoS ONE, 2016, 11, e0167167.	2.5	59
42	Cross-sector surveys assessing perceptions of key stakeholders towards barriers, concerns and facilitators to the appropriate use of adaptive designs in confirmatory trials. Trials, 2015, 16, 585.	1.6	14
43	Missing steps in a staircase: a qualitative study of the perspectives of key stakeholders on the use of adaptive designs in confirmatory trials. Trials, 2015, 16, 430.	1.6	31
44	A theory-based online health behaviour intervention for new university students (U@Uni:LifeGuide): results from a repeat randomized controlled trial. Trials, 2015, 16, 555.	1.6	51
45	The disagreeable behaviour of the kappa statistic. Pharmaceutical Statistics, 2015, 14, 74-78.	1.3	47
46	Clinical and cost effectiveness of computer treatment for aphasia post stroke (Big CACTUS): study protocol for a randomised controlled trial. Trials, 2015, 16, 18.	1.6	37
47	NOURISH, Nutritional OUtcomes from a Randomised Investigation of Intradialytic oral nutritional Supplements in patients receiving Haemodialysis: a pilot randomised controlled trial. Pilot and Feasibility Studies, 2015, 1, 11.	1.2	7
48	An Investigation of the Shortcomings of the CONSORT 2010 Statement for the Reporting of Group Sequential Randomised Controlled Trials: A Methodological Systematic Review. PLoS ONE, 2015, 10, e0141104.	2.5	31
49	The analysis of the use of †unascertained' for sudden unexpected deaths in infancy from 1988 to 2010. Archives of Disease in Childhood, 2014, 99, 300-301.	1.9	Ο
50	Estimating effect sizes for health-related quality of life outcomes. Statistical Methods in Medical Research, 2014, 23, 430-439.	1.5	9
51	Reducing waste from incomplete or unusable reports of biomedical research. Lancet, The, 2014, 383, 267-276.	13.7	982
52	A theory-based online health behaviour intervention for new university students (U@Uni): results from a randomised controlled trial. BMC Public Health, 2014, 14, 563.	2.9	71
53	The statistical interpretation of pilot trials: should significance thresholds be reconsidered?. BMC Medical Research Methodology, 2014, 14, 41.	3.1	266
54	An investigation of the impact of futility analysis in publicly funded trials. Trials, 2014, 15, 61.	1.6	16

#	Article	IF	CITATIONS
55	A survey of birth order status of students studying for medical degree at the University of Sheffield. JRSM Open, 2014, 5, 205427041453332.	0.5	1
56	A reinvestigation of recruitment to randomised, controlled, multicenter trials: a review of trials funded by two UK funding agencies. Trials, 2013, 14, 166.	1.6	295
57	A theory-based online health behavior intervention for new university students: study protocol. BMC Public Health, 2013, 13, 107.	2.9	23
58	Nutritional outcomes from a randomised investigation of intradialytic oral nutritional supplements in patients receiving haemodialysis, (NOURISH): a protocol for a pilot randomised controlled trial. SpringerPlus, 2013, 2, 515.	1.2	3
59	An audit of sample sizes for pilot and feasibility trials being undertaken in the United Kingdom registered in the United Kingdom Clinical Research Network database. BMC Medical Research Methodology, 2013, 13, 104.	3.1	523
60	Meta-analysis in clinical research. Statistical Methods in Medical Research, 2013, 22, 115-116.	1.5	0
61	Efficacy and suicidal risk for antidepressants in paediatric and adolescent patients. Statistical Methods in Medical Research, 2013, 22, 190-218.	1.5	18
62	Preventing and lessening exacerbations of asthma in school-age children associated with a new term (PLEASANT): study protocol for a cluster randomised control trial. Trials, 2013, 14, 297.	1.6	17
63	Environmental triggers of hospital admissions for school-age children with asthma in two British cities: Figure 1. Emergency Medicine Journal, 2012, 29, 844-845.	1.0	1
64	Computer Therapy Compared With Usual Care for People With Long-Standing Aphasia Poststroke. Stroke, 2012, 43, 1904-1911.	2.0	119
65	Influence of Adaptive Analysis on Unnecessary Patient Recruitment: Reanalysis of the RATPAC Trial. Annals of Emergency Medicine, 2012, 60, 442-448.e1.	0.6	5
66	Seven useful designs. Pharmaceutical Statistics, 2012, 11, 24-31.	1.3	4
67	Investigating the assumption of homogeneity of treatment effects in clinical studies with application to metaâ€analysis. Pharmaceutical Statistics, 2012, 11, 49-56.	1.3	7
68	Sample sizes for trials involving multiple correlated mustâ€win comparisons. Pharmaceutical Statistics, 2012, 11, 177-185.	1.3	21
69	Tutorial in biostatistics: sample sizes for parallel group clinical trials with binary data. Statistics in Medicine, 2012, 31, 2904-2936.	1.6	40
70	A comparison of methods for sample size estimation for non-inferiority studies with binary outcomes. Statistical Methods in Medical Research, 2011, 20, 595-612.	1.5	22
71	Seasonality of medical contacts in school-aged children with asthma: Association with school holidays. Public Health, 2011, 125, 769-776.	2.9	23
72	Rehabilitation of older patients: day hospital compared with rehabilitation at home. Clinical outcomes. Age and Ageing, 2011, 40, 557-562.	1.6	16

#	Article	IF	CITATIONS
73	Proposed best practice for statisticians in the reporting and publication of pharmaceutical industryâ€sponsored clinical trials. Pharmaceutical Statistics, 2011, 10, 70-73.	1.3	16
74	The potential for bias in reporting of industryâ€sponsored clinical trials. Pharmaceutical Statistics, 2011, 10, 74-79.	1.3	16
75	Making available information from studies sponsored by the pharmaceutical industry: some current practices. Pharmaceutical Statistics, 2011, 10, 60-69.	1.3	7
76	The ABC of nonâ€inferiority margin setting from indirect comparisons. Pharmaceutical Statistics, 2011, 10, 448-453.	1.3	15
77	Time to end the nonâ€inferiority complex?. Pharmaceutical Statistics, 2011, 10, 393-394.	1.3	1
78	Statistical issues in drug development. Statistical Methods in Medical Research, 2011, 20, 577-578.	1.5	1
79	Investigating variability in patient response to treatment – a case study from a replicate cross-over study. Statistical Methods in Medical Research, 2011, 20, 657-666.	1.5	46
80	Measurement in clinical trials: A neglected issue for statisticians?. Statistics in Medicine, 2009, 28, 3189-3209.	1.6	115
81	Authors' Rejoinder to Commentaries on â€~Measurement in clinical trials: A neglected issue for statisticians?'. Statistics in Medicine, 2009, 28, 3223-3225.	1.6	Ο
82	lssues with using baseline in last observation carried forward analysis. Pharmaceutical Statistics, 2008, 7, 142-146.	1.3	11
83	How Biased Are Indirect Comparisons, Particularly When Comparisons Are Made Over Time in Controlled Trials?. Drug Information Journal, 2008, 42, 625-633.	0.5	28
84	Are hospital league tables calculated correctly?. Public Health, 2007, 121, 902-904.	2.9	11
85	Increases in asthma hospital admissions associated with the end of the summer vacation for school-age children with asthma in two cities from England and Scotland. Public Health, 2007, 121, 482-484.	2.9	27
86	Predicting where future means will lie based on the results of the current trial. Contemporary Clinical Trials, 2007, 28, 352-357.	1.8	12
87	Literature review October–December 2006. Pharmaceutical Statistics, 2007, 6, 67-68.	1.3	Ο
88	A personal perspective on the Royal Statistical Society report of the working party on statistical issues in first-in-man studies. Pharmaceutical Statistics, 2007, 6, 75-78.	1.3	10
89	Are we getting what we pay for?. Public Health, 2006, 120, 1013-1019.	2.9	1
90	Sample size calculations for clinical studies allowing for uncertainty about the variance. Pharmaceutical Statistics, 2006, 5, 29-37.	1.3	52

#	Article	IF	CITATIONS
91	Moving statistics beyond the individual clinical trial: applying decision science to optimize a clinical development plan. Pharmaceutical Statistics, 2005, 4, 37-46.	1.3	38
92	Why do we use pooled variance analysis of variance?. Pharmaceutical Statistics, 2005, 4, 3-5.	1.3	15
93	Sample size of 12 per group rule of thumb for a pilot study. Pharmaceutical Statistics, 2005, 4, 287-291.	1.3	1,632
94	Issues with number needed to treat. Statistics in Medicine, 2005, 24, 3233-3235.	1.6	18
95	Two-sided confidence intervals for the single proportion: comparison of seven methods by Robert G. Newcombe,Statistics in Medicine 1998;17:857–872. Statistics in Medicine, 2005, 24, 3383-3384.	1.6	71
96	Letter to the Editors. Biometrics, 2004, 60, 284-284.	1.4	6
97	Sample sizes for clinical trials with Normal data. Statistics in Medicine, 2004, 23, 1921-1986.	1.6	451
98	Sample sizes for estimation in clinical research. Pharmaceutical Statistics, 2004, 3, 213-215.	1.3	27
99	Using confidence intervals around individual means to assess statistical significance between two means. Pharmaceutical Statistics, 2004, 3, 217-222.	1.3	176
100	Designing clinical trials with uncertain estimates of variability. Pharmaceutical Statistics, 2004, 3, 261-268.	1.3	18
101	The ABC of pharmaceutical trial design: some basic principles. Pharmaceutical Statistics, 2002, 1, 45-53.	1.3	7
102	Atmospheric pressure and sudden infant death syndrome in Cook County, Chicago. Paediatric and Perinatal Epidemiology, 2001, 15, 287-289.	1.7	10
103	Problems with the performance of the SF-36 among people with type 2 diabetes in general practice. Quality of Life Research, 2001, 10, 661-670.	3.1	63
104	Repeated measures in clinical trials: analysis using mean summary statistics and its implications for design by L. Frison and S.J. Pocock,Statistics in Medicine 1992; 12: 1685-1704. Statistics in Medicine, 2000, 19, 3133-3135.	1.6	3
105	WHY ARE PHARMACOKINETIC DATA SUMMARIZED BY ARITHMETIC MEANS?. Journal of Biopharmaceutical Statistics, 2000, 10, 55-71.	0.8	90
106	LETTER TO THE EDITOR: SAMPLE SIZES CALCULATIONS FOR ORDERED CATEGORICAL DATA by J. Whitehead,Statistics in Medicine, 12, 2257-2272 (1993) , 1996, 15, 1065-1066.		8
107	LETTER TO THE EDITOR: SAMPLE SIZES CALCULATIONS FOR ORDERED CATEGORICAL DATA by J. Whitehead, Statistics in Medicine, 12, 2257–2272 (1993) Statistics in Medicine, 1996, 15, 1065-1066.	1.6	1
108	A postal survey of the quality of long-term institutional care. International Journal of Geriatric Psychiatry, 1994, 9, 619-625.	2.7	8

#	Article	IF	CITATIONS
109	Confounding and Simpson's paradox. BMJ: British Medical Journal, 1994, 309, 1480-1481.	2.3	132
110	Sample Sizes for Clinical Trials. , 0, , .		98